According to filings with the U.S. Securities and Exchange Commission, Curve Biosciences is raising up to $20,038,985.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Ritish Patnaik played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Curve Biosciences
Curve Biosciences (Curve) is a company unlocking the potential of Chronic Epigenetics to bring precision to chronic disease care. Curve creates products that target the biological changes in tissues that result in the development and progression of chronic diseases. Curves Whole Body Tissue Atlas (WBTA) uniquely allows the company to discover these precise changes with data from over 250,000 tissues across more than 1,000 clinical studies. We are dedicated to improving our patients lives and supporting our employees dreams.

To learn more about Curve Biosciences, visit https://www.curvebio.com/

Contact:
Ritish Patnaik, Chief Executive Officer
214-680-9460
https://www.linkedin.com/in/ritish/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.